Prescribing Guidance:

Guidance below should be read in conjunction with NICE guidance via: http://www.nice.org.uk/guidance/ng17

Given the availability of biosimilars and different strengths of a variety of insulin preparations, the MHRA have released guidance around the prescribing of insulin preparations: https://www.gov.uk/drug-safety-update/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error

Doncaster & Bassetlaw Medicines Formulary

Section 6.1.1: Insulins

Short Acting Insulins

Actrapid
Novorapid
Humalog (including Humalog 200units/ml Kwikpen)
Apidra

Intermediate and Long Acting Insulins

Humulin I

Lantus
Abasaglar
Toujeo (available as 300units/ml Solostar)

Levemir

Humulin M3
Novomix 30

Humalog Mix 25
Humalog Mix 50

Approved by Drug and Therapeutics Committee: October 2016
Review Date: October 2019

KEY: [UL] Unlicensed Preparation; Drug – first line choice; Drug – hospital only; Drug – Amber (TLS), Drug – Red (TLS), see http://medicinesmanagement.doncasterpct.nhs.uk/
Items for Restricted Prescribing:

Insulin Degludec may be of use in a small subgroup of patients who fail to maintain glycaemic control overnight and in whom nocturnal hypoglycaemia is an issue despite optimisation of medication regimen or those with an unpredictable lifestyle, e.g. shift workers.

Given the cost of this insulin it should be reserved for those patients who have previously tried other cheaper insulin analogues.

NICE guidance relating to this insulin can be found here.  
Type 1 Diabetes  
Type 2 Diabetes

Insulin Degludec/Liraglutide (Xultophy) is available for diabetic specialists to prescribe where the combination of a GLP-1 receptor agonists and insulin are indicated. Prescribing should be retained within specialist services.